about
A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616]New developments in the genetics, pathogenesis, and therapy of IgA nephropathyMefunidone attenuates tubulointerstitial fibrosis in a rat model of unilateral ureteral obstructionPredicting progression of IgA nephropathy: new clinical progression risk score.Glomerular density in renal biopsy specimens predicts the long-term prognosis of IgA nephropathy.A molecular signature of proteinuria in glomerulonephritis.Optimal proteinuria target for renoprotection in patients with IgA nephropathy.Effects of vitamin D on renal fibrosis in diabetic nephropathy model ratsTime-averaged albumin predicts the long-term prognosis of IgA nephropathy patients who achieved remission.Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy.Validation of the Oxford classification of IgA nephropathy for pediatric patients from China.Mortality of IgA nephropathy patients: a single center experience over 30 yearsAberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathyClinical features and outcomes of IgA nephropathy with nephrotic syndrome.Predicting the risk for dialysis or death in IgA nephropathy.Effect of treatment on urinary kidney injury molecule-1 in IgA nephropathyAstragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathyTacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy.Anti-proteinuric effect of sulodexide in immunoglobulin a nephropathy.Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the ratProhibitin attenuates oxidative stress and extracellular matrix accumulation in renal interstitial fibrosis disease.Progression of glomerular and tubular disease in pediatrics.Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trialPlasma neutrophil gelatinase-associated lipocalin as a potential predictor of adverse renal outcomes in immunoglobulin A nephropathy.Implication of urinary complement factor H in the progression of immunoglobulin A nephropathy.Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in childrenValidation study of oxford classification of IgA nephropathy: the significance of extracapillary proliferation.Circulating Tumor Necrosis Factor α Receptors Predict the Outcomes of Human IgA Nephropathy: A Prospective Cohort Study.Increased venous proinflammatory gene expression and intimal hyperplasia in an aorto-caval fistula model in the rat.Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathyThe use of the Oxford classification of IgA nephropathy to predict renal survivalLow Birth Weight and Risk of Progression to End Stage Renal Disease in IgA Nephropathy--A Retrospective Registry-Based Cohort Study.Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study.Serum galactose-deficient IgA1 level is not associated with proteinuria in children with IgA nephropathy.GSTA3 Attenuates Renal Interstitial Fibrosis by Inhibiting TGF-Beta-Induced Tubular Epithelial-Mesenchymal Transition and Fibronectin Expression.QiShenYiQi Attenuates Renal Interstitial Fibrosis by Blocking the Activation of β-Catenin.Vitamin D deficiency may predict a poorer outcome of IgA nephropathyUpdate on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects.Hyperuricemia as a marker for progression of immunoglobulin A nephropathy.Endothelin-1 and the kidney--beyond BP.
P2860
Q24800133-0ECC3A8C-390E-45F4-A712-78F7AC00EF60Q26786248-3B97F84C-1DA0-4032-9B0A-05FE8DF567ACQ28547858-1ECDA80C-58E2-48EE-A6E1-670169A76CABQ31068314-C6671937-D3F6-48AD-9FB0-5BAF4E0D2AEFQ33571375-3ADCD6F8-CB95-4CD6-8C72-D4CD5A31AB16Q33728335-760930B5-E980-4D6E-A242-383111E69477Q33864287-9F916A01-993C-477A-8DE5-95B379C76AA5Q33898491-DCE6D519-2773-449D-8592-EF315F7CF844Q33906377-B8640CEB-2BA8-4BF8-9313-4157FF0ECFA2Q34336417-253097E4-5DCF-496D-9CC6-43801DE22589Q34488531-360B38D4-951D-4CCF-9709-2878B7D04370Q34506767-F3BF7735-7808-4E1B-BA93-CD0EC9DCA91EQ34557198-980FD43C-AE8C-4A70-9E27-B425A43D4270Q34660643-269D03DB-CBE4-4C6D-9897-7B8E542CBFA3Q34726899-3A6A2D45-0022-4E31-87FF-BDA9B4AC7682Q34803229-C0363730-394D-426B-B608-30A8797747A8Q34837833-A023FB51-B837-4A91-9271-11CBCD68BBBAQ34971424-6D14BEA5-D119-47B9-BF09-736B2F26CBB8Q35014833-7FA72355-4F37-4CCA-AEFA-31D5A51DBD32Q35015952-8320033B-1554-424B-BCE1-D052C0C61BD1Q35035081-83ED819E-F85D-4025-A6A2-EA5376500A36Q35234337-6078DB7F-9C40-47C4-964D-5AE44DF2EFF4Q35623623-C5743622-043B-49F1-90A4-9D33CEB03CECQ35626252-FA120AE2-1627-4B44-9AC3-6F27206DAB47Q35649890-CDDD78E3-714D-4CD9-B2A9-F2F883717D7FQ35657080-894BD753-BD1C-4774-A832-9CA1F07C5343Q35664626-2E7126A7-D0EB-4A9D-9DB8-C7451AE15A6CQ35692544-B3F9ACC2-2D31-4457-A91A-7F6CFF5002B0Q35791476-2A8FBC06-EB7B-4C0D-8163-0F2B85DDDCB5Q35917473-8049D67E-D06C-4984-B77E-11D5D1542233Q35985818-159BF93D-C2B3-43EA-BB93-F4AD76A06933Q35993496-9013B922-2DD4-44A5-AC8B-53D7D02E0DCAQ36003136-334DA99E-66BA-442A-895E-3B6B7110B2BDQ36057636-5F83F812-8361-404C-ADAA-08B9B91EE770Q36125061-2C2DA3F2-594D-4B27-8096-13793D7ABC19Q36135728-C1FBE484-2E38-4ABF-8A35-F5BA34C8EBADQ36180594-A74E50BB-17F7-4BEE-A951-27FF39091B71Q36447934-E8BC08B2-FC40-449C-A753-75F3E3165947Q36471731-25F45239-0430-468F-997D-BE680385D706Q36619734-27F6711B-5186-4E79-84F1-8E5493DA5511
P2860
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Predicting renal outcome in IgA nephropathy.
@en
type
label
Predicting renal outcome in IgA nephropathy.
@en
prefLabel
Predicting renal outcome in IgA nephropathy.
@en
P2093
P1476
Predicting renal outcome in IgA nephropathy.
@en
P2093
Bergstralh EJ
Donadio JV Jr
Radford MG Jr
P304
P577
1997-02-01T00:00:00Z